Lipid nanoparticles for engineering next generation CAR T cell immunotherapy.

Area of Science:

• Biotechnology
• Immunotherapy
• Nanomedicine

Background:

• Chimeric antigen receptor (CAR) T cell therapy offers significant potential for treating various cancers.
• Current CAR T cell production methods face limitations and challenges, impacting efficacy and accessibility.

Purpose of the Study:

• To review the application of lipid nanoparticles (LNPs) in improving CAR T cell immunotherapy.
• To explore how LNPs can address challenges in CAR T cell production, including *ex vivo* and *in vivo* methods.

Main Methods:

• Review of current literature on CAR T cell therapy and LNP technology.
• Analysis of LNP design strategies for CAR T cell activation and gene delivery.
• Discussion of innovations in *ex vivo* and *in vivo* CAR T cell production facilitated by LNPs.

Main Results:

• Lipid nanoparticles (LNPs) can be rationally designed to overcome limitations in CAR T cell therapy.
• Antigen-presenting cell-mimetic LNPs offer a streamlined approach for CAR T cell production.
• LNPs show potential for enabling *in vivo* CAR T cell production, a transformative alternative to current methods.

Conclusions:

• LNP-based strategies hold significant promise for advancing CAR T cell immunotherapy.
• Further research and development are needed to address safety, manufacturing, and regulatory aspects for clinical translation.
• LNPs may revolutionize CAR T cell therapy by improving production efficiency and enabling *in vivo* approaches.